VENTURE LIFE GROUP PLC — Board/Management Information 2017

Mar 1, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1262Y

Venture Life Group PLC

01 March 2017

Venture Life Group plc

("Venture Life" or the "Group")

Directorate Change

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces the appointment of Adrian Crockett as Chief Financial Officer, effective as of 6 March 2017.

Adrian joins Venture Life from Abbott Diabetes Care Ltd, a division of Abbott Laboratories with an annual turnover of approximately $1 billion, where he was Finance Director since October 2011 and responsible for a team of 14 qualified finance staff, reporting directly to the unit's Managing Director.

Before that, Adrian was a Financial Controller within PAREXEL, a global Clinical Research Organisation with a turnover of $2 billion, and prior to that held a number of Finance and Planning roles within organisations such as GlaxoSmithKline plc, Novartis Vaccines & Diagnostics, Inc., and Anderson Consulting (now Accenture).

Jerry Randall, CEO of Venture Life, commented: "I am delighted to welcome Adrian to the Board as Chief Financial Officer. Adrian has pursued an active career within the healthcare space, and has enjoyed senior roles within some of the best known healthcare companies in the world. With this extensive experience, in particular in consumer healthcare and manufacturing operations, we are confident Adrian will make a significant contribution to our business as we continue to grow and deliver on our strategy of becoming sustainably profitable."

Information to be disclosed under Schedule 2(g) and Rule 17 of the AIM rules

Adrian Graham Crockett (aged 49)

Current Directorships	Directorships in the last five years
none	Abbott Diabetes Care Limited

Other than the information contained in this announcement, there is no further information required to be disclosed under Rule 17 and Schedule Two, paragraph (g) of the AIM Rules.

For further information please contact:

Venture Life Group PLC		+44 (0) 1344 742 870
Jerry Randall, Chief Executive Officer
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)		+44 (0) 20 7886 2500
Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Turner Pope Investments (TPI) Ltd (Joint Broker)		+44 (0) 20 3621 4120
James Pope/Ben Turner
Walbrook PR	venturelife@walbrookpr.com or +44 (0) 20 7933 8780
Paul McManus/Anna Dunphy	+44 (0) 7980 541 893/ +44 (0) 7876 741 001

This announcement contains information which, prior to its disclosure, was inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABRGDDIXDBGRI